| First Author | Shimada T | Year | 2004 |
| Journal | Biochem Biophys Res Commun | Volume | 314 |
| Issue | 2 | Pages | 409-14 |
| PubMed ID | 14733920 | Mgi Jnum | J:87977 |
| Mgi Id | MGI:3028773 | Doi | 10.1016/j.bbrc.2003.12.102 |
| Citation | Shimada T, et al. (2004) FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314(2):409-14 |
| abstractText | Fibroblast growth factor (FGF)-23 was identified as a causative factor of tumor-induced osteomalacia and also as a responsible gene for autosomal dominant hypophosphatemic rickets. To clarify the pathophysiological roles of FGF-23 in these diseases, we generated its transgenic mice. The transgenic mice expressing human FGF-23 reproduced the common clinical features of these diseases such as hypophosphatemia probably due to increased renal phosphate wasting, inappropriately low serum 1,25-dihydroxyvitamin D level, and rachitic bone. The renal phosphate wasting in the transgenic mice was accompanied by the reduced expression of sodium phosphate cotransporter type IIa in renal proximal tubules. These results reinforce the notion that the excessive action of FGF-23 plays a causative role in the development of several hypophosphatemic rickets/osteomalacia. |
